Axial Spondyloarthritis
Patients with rheumatoid arthritis, PsA, AS ‘stuck in a cycle of long-term opioid use’
Patients with rheumatic diseases demonstrate a high reliance on opioids around the time of diagnosis, and significant numbers of patients were not on appropriate treatment in the year afterward, according to data in Clinical Rheumatology.
TNF inhibitor efficacy in axial spondyloarthritis varies greatly by sex via BASDAI score
The effectiveness of TNF inhibitors for axial spondyloarthritis varies significantly between men and women based on BASDAI score, but not ASDAS, according to data published in Arthritis Research & Therapy.
Discontinuing biologics in axial spondyloarthritis 'not a good idea'
DESTIN, Fla. — New data on discontinuation or dose reduction of biologic therapies has led to a shifting landscape in axial spondyloarthritis management, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.
Axial spondyloarthritis can be ‘reliably diagnosed’ shortly after chronic back pain onset
Most patients with recent-onset chronic back pain suspected of axial spondyloarthritis can be “unequivocally and reliably diagnosed” at their first rheumatology visit, according to data published in the Annals of the Rheumatic Diseases.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
‘This gives us more leeway’: Intravenous secukinumab effective in axial spondyloarthritis
SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.
Ixekizumab reduces erosion, increases backfill scores in radiographic axial SpA
SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.
Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks
Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.
Taking ‘shots on goal’: The continuing fight to bring precision medicine to rheumatology
Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.
Patients with axial spondyloarthritis exhibit shared microbiome dysbiosis
Patients with axial spondyloarthritis and other related inflammatory diseases demonstrate common microbiome dysfunction characteristics, according to data published in Arthritis & Rheumatology.